Latanoprost Eye Drops, as a prostaglandin medicine (one of the first-line treatments for open-angle glaucoma or ocular hypertension), is developed with LipixelleTM technology that dissolves latanoprost with non-ionic surfactants, and can achieve BAK-free delivery to avoid the potential ocular damage caused by long-term use of BAK. The product has been approved for marketing in the U.S.
The prevalence of primary open-angle glaucoma with ocular hypertension in China is estimated to be 1.5% to 2%, with more than 20 million people. Latanoprost Eye Drops is expected to be a safe and effective treatment option for patients suffering from relevant diseases.
